Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Dec 2:18:1276-1283.
doi: 10.12659/ajcr.905340.

Homeopathic Treatment of Vitiligo: A Report of Fourteen Cases

Seema Mahesh  1 , Mahesh Mallappa  1 , Dionysios Tsintzas  2 , George Vithoulkas  3
Affiliations
Case Reports

Homeopathic Treatment of Vitiligo: A Report of Fourteen Cases

Seema Mahesh et al. Am J Case Rep. .

Abstract

BACKGROUND Vitiligo, also known as leukoderma, is an autoimmune skin condition that results in the loss of melanin pigment. Vitiligo is not a rare condition but is difficult to treat and is associated with psychological distress. CASE REPORT A series of 14 cases of vitiligo are presented that were treated with individualized homeopathic remedies that were based on plant, animal, or mineral compounds. There were 13 women and one man in the case series, with a mean age 29.8 years, and a mean follow-up from treatment of 58 months. The mean time between the onset of the appearance of vitiligo and the first consultation at our clinic was 96 months. Homeopathic treatment for patients is holistic and was performed on an individualized basis as described in this case series. Photographic images of the skin are presented before and after treatment. CONCLUSIONS In 14 patients with vitiligo treated with individualized homeopathy, the best results were achieved in the patients who were treated in the early stages of the disease. We believe that homeopathy may be effective in the early stages of vitiligo, but large controlled clinical studies are needed in this area.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

Conflict of interest

None.

Figures

Figure 1.
Figure 1.
Case 1. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
Figure 2.
Figure 2.
Case 2. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
Figure 3.
Figure 3.
Case 3. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
Figure 4.
Figure 4.
Case 4. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
Figure 5.
Figure 5.
Case 5. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
Figure 6.
Figure 6.
Case 6. (A) The appearance of the skin before treatment. (B) The appearance of the skin before treatment. (C) The appearance of the skin during treatment. (D) The appearance of the skin during treatment.
Figure 7.
Figure 7.
Case 7. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
Figure 8.
Figure 8.
Case 8. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
Figure 9.
Figure 9.
Case 9. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
Figure 10.
Figure 10.
Case 10. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
Figure 11.
Figure 11.
Case 11. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
Figure 12.
Figure 12.
Case 12. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
Figure 13.
Figure 13.
Case 13. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
Figure 14.
Figure 14.
Case 14. (A) The appearance of the skin before treatment. (B) The appearance of the skin during treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jain A, Mal J, Mehndiratta V, et al. Study of oxidative stress in vitiligo. Indian J Clin Biochem. 2010;26(1):78–81. - PMC - PubMed
    1. Taieb A. Intrinsic and extrinsic pathomechanisms in vitiligo. Pigment Cell Res. 2000;13(S8):41–47. - PubMed
    1. Jin Y, Birlea S, Fain P, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. New Engl J Med. 2010;362(18):1686–97. - PMC - PubMed
    1. Alghamdi KM, Khurrum H, Taieb A, Ezzedine K. Treatment of generalized vitiligo with anti-TNF-α agents. J Drugs Dermatol. 2012;11(4):534–39. - PubMed
    1. Manga P, Elbuluk N, Orlow SJ. Recent advances in understanding vitiligo. F1000Research. 2016;5:F1000. Faculty Rev-2234. - PMC - PubMed

Publication types